ANAPTYSBIO, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
ANAPTYSBIO, INC. (ANAB) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $959.00 thousand for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-09-21
- ANAPTYSBIO, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $479.00K, a 4.36% increase year-over-year.
- ANAPTYSBIO, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $480.00K, a 4.35% increase year-over-year.
- ANAPTYSBIO, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $475.00K, a 4.17% increase year-over-year.
- ANAPTYSBIO, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $470.00K, a 3.98% increase year-over-year.
- ANAPTYSBIO, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.86M, a 4.08% increase from fiscal 2024.
- ANAPTYSBIO, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.79M, a 3.89% increase from fiscal 2023.
- ANAPTYSBIO, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.72M, a 3.86% increase from fiscal 2022.
- ANAPTYSBIO, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.66M, a 12.85% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $479.00K derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $959.00K 10-KT · filed 2026-09-21 | $1.43M derived: sum of 3 quarters · filed 2026-09-21 | $1.90M derived: sum of 4 quarters · filed 2026-09-21 |
| 2026-03-31 | $480.00K 10-Q · filed 2026-05-12 | $955.00K derived: sum of 2 quarters · filed 2026-09-21 | $1.43M derived: sum of 3 quarters · filed 2026-09-21 | $1.88M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-12-31 | $475.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $945.00K derived: sum of 2 quarters · filed 2026-09-21 | $1.40M derived: sum of 3 quarters · filed 2026-09-21 | $1.86M 10-KT · filed 2026-09-21 |
| 2025-09-30 | $470.00K derived: 10-Q 9 month − 10-KT 6 month · filed 2025-11-04 | $929.00K derived: sum of 2 quarters · filed 2026-09-21 | $1.39M 10-Q · filed 2025-11-04 | $1.84M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-06-30 | $459.00K derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $919.00K 10-KT · filed 2026-09-21 | $1.38M derived: sum of 3 quarters · filed 2026-09-21 | $1.83M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-03-31 | $460.00K 10-Q · filed 2026-05-12 | $916.00K derived: sum of 2 quarters · filed 2026-09-21 | $1.37M derived: sum of 3 quarters · filed 2026-09-21 | $1.81M derived: sum of 4 quarters · filed 2026-09-21 |
| 2024-12-31 | $456.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $908.00K derived: sum of 2 quarters · filed 2026-09-21 | $1.35M derived: sum of 3 quarters · filed 2026-09-21 | $1.79M 10-KT · filed 2026-09-21 |
| 2024-09-30 | $452.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $893.00K derived: sum of 2 quarters · filed 2025-11-04 | $1.33M 10-Q · filed 2025-11-04 | $1.77M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $441.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $883.00K 10-Q · filed 2025-08-06 | $1.32M derived: sum of 3 quarters · filed 2026-03-03 | $1.76M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $442.00K 10-Q · filed 2025-05-05 | $881.00K derived: sum of 2 quarters · filed 2026-03-03 | $1.31M derived: sum of 3 quarters · filed 2026-03-03 | $1.74M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $439.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $873.00K derived: sum of 2 quarters · filed 2026-03-03 | $1.30M derived: sum of 3 quarters · filed 2026-03-03 | $1.72M 10-K · filed 2026-03-03 |
| 2023-09-30 | $434.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $858.00K derived: sum of 2 quarters · filed 2024-11-05 | $1.28M 10-Q · filed 2024-11-05 | $1.71M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $424.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $851.00K 10-Q · filed 2024-08-05 | $1.27M derived: sum of 3 quarters · filed 2025-02-27 | $1.69M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $427.00K 10-Q · filed 2024-05-09 | $849.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.27M derived: sum of 3 quarters · filed 2025-02-27 | $1.68M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $422.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $841.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.25M derived: sum of 3 quarters · filed 2025-02-27 | $1.66M 10-K · filed 2025-02-27 |
| 2022-09-30 | $419.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $827.00K derived: sum of 2 quarters · filed 2023-11-02 | $1.24M 10-Q · filed 2023-11-02 | $1.46M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-06-30 | $408.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $819.00K 10-Q · filed 2023-08-07 | $1.04M derived: sum of 3 quarters · filed 2024-03-11 | $1.54M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-03-31 | $411.00K 10-Q · filed 2023-05-11 | $631.00K derived: sum of 2 quarters · filed 2024-03-11 | $1.13M derived: sum of 3 quarters · filed 2024-03-11 | $1.76M derived: sum of 4 quarters · filed 2024-03-11 |
| 2021-12-31 | $220.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $720.00K derived: sum of 2 quarters · filed 2024-03-11 | $1.34M derived: sum of 3 quarters · filed 2024-03-11 | $1.47M 10-K · filed 2024-03-11 |
| 2021-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.13M derived: sum of 2 quarters · filed 2022-11-08 | $1.25M 10-Q · filed 2022-11-08 | $1.73M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $625.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $751.00K 10-Q · filed 2022-08-08 | $1.23M derived: sum of 3 quarters · filed 2023-03-01 | $1.43M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $126.00K 10-Q · filed 2022-05-04 | $605.00K derived: sum of 2 quarters · filed 2023-03-01 | $802.00K derived: sum of 3 quarters · filed 2023-03-01 | |
| 2020-12-31 | $479.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $676.00K derived: sum of 2 quarters · filed 2023-03-01 | $1.06M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $197.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $579.00K 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $382.00K 10-Q · filed 2021-08-09 | |||
| 2019-12-31 | $893.00K 10-K · filed 2022-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |